- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
AstraZeneca is a research-based pharmaceutical company that is currently reshaping its clinical development under the initiative "Predictive Science". Model-based drug development (MBDD) plays a major part in this effort.
There are over 20 pharmacometricians working in fields closely related to the DDMLF topic and the solutions proposed by the DDMoRe Consortium. Joachim Grevel is the Global Discipline Lead for pharmacometrics in AstraZeneca with 25 years of experience in population-style modelling. He, or whoever he delegates, will be competent to work together with the academic and SME partners on the proposed tasks.